Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines

Chest

Volumn 143, Issue 5 SUPPL, 2013, Pages

  Silvestri, Gerard A ^a   Gonzalez, Anne V ^b   Jantz, Michael A ^c   Margolis, Mitchell L ^d   Gould, Michael K ^e   Tanoue, Lynn T ^f   Harris, Loren J ^h   Detterbeck, Frank C ^g  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e KAISER PERMANENTE   (United States)

^f Section of Pulmonary and Critical Care Medicine   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER GRADING; CANCER STAGING; CLINICAL EVALUATION; COMORBIDITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; ENDOBRONCHIAL ULTRASONOGRAPHY; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MEDIASTINOSCOPY; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; THORACOSCOPY; TRANSBRONCHIAL ASPIRATION; TRANSTHORACIC BIOPSY; VIDEO ASSISTED THORACOSCOPIC SURGERY; VISCERAL METASTASIS;

EID: 84877611694     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2355     Document Type: Article

References (362)

1. Lewis SZ, Diekemper R, Addrizzo-Harris DJ. Methodology for development of guidelines for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5)(suppl): 41S-50S.
2. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5) (suppl): e400S-e419S.
3. Detterbeck FC, Jantz MA, Wallace M, et al. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(suppl 3): 202S-220S.
4. Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidencedbased clinical practice guidelines (2nd edition). Chest. 2007; 132(suppl 3):178S-201S.
5. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5) (suppl): e142S-e165S.
6. Farjah F, Flum DR, Ramsey SD, Heagerty PJ, Symons RG, Wood DE. Multi-modality mediastinal staging for lung cancer among medicare beneficiaries. J Thorac Oncol. 2009; 4 (3): 355-363.
7. Little AG, Rusch VW, Bonner JA, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg. 2005; 80 (6): 2051-2056.
8. Tsang GM, Watson DC. The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer. Thorax. 1992; 47 (1): 3-5.
9. Toloza EM, Harpole L, Detterbeck F, McCrory DC. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003; 123 (suppl 1): 157S-166S.
10. Toloza E, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003; 123(suppl 1): 137S-146S.
11. Eschmann SM, Friedel G, Paulsen F, et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging. 2002; 29 (6): 804-808.
12. Farrell MA, McAdams HP, Herndon JE, Patz EF Jr. Nonsmall cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology. 2000; 215(3): 886-890.
13. Grant D, Edwards D, Goldstraw P. Computed tomography of the brain, chest, and abdomen in the preoperative assessment of non-small cell lung cancer. Thorax. 1988; 43 (11): 883-886.
14. Ichinose Y, Hara N, Ohta M, et al. Preoperative examination to detect distant metastasis is not advocated for asymptomatic patients with stages 1 and 2 non-small cell lung cancer. Preoperative examination for lung cancer. Chest. 1989; 96 (5): 1104-1109.
15. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys. 2001; 50 (2): 287-293.
16. Michel F, Solèr M, Imhof E, Perruchoud AP. Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax. 1991; 46 (7): 469-473.
17. Modini C, Passariello R, Iascone C, et al. TNM staging in lung cancer: role of computed tomography. J Thorac Cardiovasc Surg. 1982; 84 (4): 569-574.
18. Quinn DL, Ostrow LB, Porter DK, Shelton DK Jr, Jackson DE Jr. Staging of non-small cell bronchogenic carcinoma. Relationship of the clinical evaluation to organ scans. Chest. 1986; 89 (2): 270-275.
19. Reed CE, Harpole DH, Posther KE, et al; American College of Surgeons Oncology Group Z0050 trial. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003; 126 (6): 1943-1951.
20. Salvatierra A, Baamonde C, Llamas JM, Cruz F, Lopez-Pujol J. Extrathoracic staging of bronchogenic carcinoma. Chest. 1990; 97 (5): 1052-1058.
21. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol. 2004; 22 (12): 2357-2362.
22. Weder W, Schmid RA, Bruchhaus H, Hillinger S, von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg. 1998; 66 (3): 886-892.
23. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005; 130 (1): 151-159.
24. Pozo-Rodríguez F, Martín de Nicolás JL, Sánchez-Nistal MA, et al. Accuracy of helical computed tomography and [18 F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol. 2005; 23 (33): 8348-8356.
25. Serra M, Cirera L. Routine positron tomography (PET) and selective mediastinoscopy is as good as routine mediastinoscopy to rule out N2 disease in non-small cell lung cancer (NSCLC). J Clin Oncol. 2006; 24:371S.
26. Verhagen AFT, Bootsma GP, Tjan-Heijnen VCG, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer. 2004; 44 (2): 175-181.
27. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009; 361 (1): 32-39.
28. Herder GJ, Kramer H, Hoekstra OS, et al; POORT Study Group. Traditional versus up-front [18 F] fluorodeoxyglucosepositron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol. 2006; 24 (12): 1800-1806.
29. Maziak DE, Darling GE, Inculet RI, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med. 2009; 151(4):221-228, W-248.
30. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002; 359 (9315): 1388-1393.
31. Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R. The effect of FDG-PET on the stage distribution of non-small cell lung cancer. J Thorac Oncol. 2008; 3 (2): 135-139.
32. Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R. Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. J Thorac Oncol. 2009; 4 (12): 1524-1529.
33. Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN Jr. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med. 2008; 168(14): 1541-1549.
34. Kozower BD, Meyers BF, Reed CE, Jones DR, Decker PA, Putnam JB Jr. Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer? Ann Thorac Surg. 2008; 85 (4): 1166-1169., discussion 1169-1170.
35. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5)(suppl): e278S-e313S.
36. Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. Am J Respir Crit Care Med. 1995; 152 (1): 225-230.
37. Mohammed N, Kestin LL, Grills IS, et al. Rapid disease progression with delay in treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011; 79 (2): 466-472.
38. Alonso Moralejo R, Sayas Catalán J, García Luján R, Coronado Poggio M, Monsó Molas E, López Encuentra A. Use of positron emission tomography in assessing hidden extrathoracic metastasis in non small cell lung cancer [in Spanish]. Arch Bronconeumol. 2010; 46 (5): 238-243.
39. Chiba K, Isoda M, Chiba M, Kanematsu T, Eguchi S. Significance of PET/CT in determining actual TNM staging for patients with various lung cancers. Int Surg. 2010; 95 (3): 197-204.
40. Lee BE, von Haag D, Lown T, Lau D, Calhoun R, Follette D. Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007; 133 (3): 746-752.
41. Prévost A, Papathanassiou D, Jovenin N, et al. Comparison between PET(-FDG) and computed tomography in the staging of lung cancer. Consequences for operability in 94 patients [in French]. Rev Pneumol Clin. 2009; 65 (6): 341-349.
42. Rodríguez Fernández A, Bellón Guardia ME, Gómez Río M, et al. Staging of non-small cell lung cancer. Diagnosis effi-cacy of structural (CT) and functional (FDG-PET) imaging methods [in Spanish]. Rev Clin Esp. 2007; 207 (11): 541-547.
43. Sharma R, Tripathi M, D'Souza M, et al. The importance of 18 F-FDG PET/CT, CT and X-rays in detecting primary stage III A lung cancer and the incidence of extra thoracic metastases. Hell J Nucl Med. 2009; 12 (1): 22-25.
44. De Wever W, Ceyssens S, Mortelmans L, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol. 2007; 17 (1): 23-32.
45. Heo EY, Yang SC, Yoo CG, Han SK, Shim YS, Kim YW. Impact of whole-body 18 F-fluorodeoxyglucose positron emission tomography on therapeutic management of nonsmall cell lung cancer. Respirology. 2010; 15 (8): 1174-1178.
46. Margery J, Milleron B, Vaylet F, et al. Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study [in French]. Rev Pneumol Clin. 2010; 66 (5): 313-320.
47. Subedi N, Scarsbrook A, Darby M, Korde K, Mc Shane P, Muers MF. The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer. Lung Cancer. 2009; 64 (3): 301-307.
48. Lu Y, Xie D, Huang W, Gong H, Yu J. 18 F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients. Neoplasma. 2010; 57 (2): 129-134.
49. Ozcan Kara P, Kara T, Kara Gedik G, et al. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Nucl Med Commun. 2011; 32 (2): 106-112.
50. Grassetto G, Fornasiero A, Bonciarelli G, et al. Additional value of FDG-PET/CT in management of "solitary" liver metastases: preliminary results of a prospective multicenter study. Mol Imaging Biol. 2010; 12 (2): 139-144.
51. Song JW, Oh YM, Shim TS, Kim WS, Ryu JS, Choi CM. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer. 2009; 65 (3): 333-338.
52. Akamatsu H, Tsuya A, Kaira K, et al. Intestinal metastasis from non-small-cell lung cancer initially detected by 18 F-fluorodeoxyglucose positron emission tomography. Jpn J Radiol. 2010; 28 (9): 684-687.
53. Lee JW, Kim SK, Park JW, Lee HS. Unexpected small bowel intussusception caused by lung cancer metastasis on 18 F-fluorodeoxyglucose PET-CT. Ann Thorac Surg. 2010; 90 (6): 2037-2039.
54. Purandare NC, Rangarajan V, Pramesh CS, Rajnish A, Shah S, Dua SG. Isolated asymptomatic skeletal muscle metastasis in a potentially resectable non-small cell lung cancer: detection with FDG PET-CT scanning. Cancer Imaging. 2008; 8 : 216-219.
55. Lee HY, Chung JK, Jeong JM, et al. Comparison of FDGPET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer. Ann Nucl Med. 2008; 22 (4): 281-286.
56. De Wever W, Bruyeer E, Demaerel P, Wilms G, Coolen J, Verschakelen J. Staging of lung cancer. Do we need a diagnostic CT of the brain after an integrated PET/CT for the detection of brain metastases? JBR-BTR. 2010; 93 (2): 71-76.
57. Koo HK, Jin SM, Lee CH, et al. Factors associated with recurrence in patients with curatively resected stage I-II lung cancer. Lung Cancer. 2011; 73 (2): 222-229.
58. Nishikawa T, Ueba T, Kawashima M, et al. Early detection of metachronous brain metastases by biannual brain MRI follow-up may provide patients with non-small cell lung cancer with more opportunities to have radiosurgery. Clin Neurol Neurosurg. 2010; 112 (9): 770-774.
59. Sánchez de Cos J, Sojo González MA, Montero MV, Pérez Calvo MC, Vicente MJ, Valle MH. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer. 2009; 63 (1): 140-145.
60. Schreyögg J, Weller J, Stargardt T, et al. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer. J Nucl Med. 2010; 51 (11): 1668-1675.
61. Wauters I, Stroobants S, De Leyn P, et al. Impact of FDGPET-induced treatment choices on long-term outcome in non-small cell lung cancer. Respiration. 2010; 79 (2): 97-104.
62. Søgaard R, Fischer BM, Mortensen J, Højgaard L, Lassen U. Preoperative staging of lung cancer with PET/CT: costeffectiveness evaluation alongside a randomized controlled trial. Eur J Nucl Med Mol Imaging. 2011; 38 (5): 802-809.
63. Borrego Dorado I, López García C, Vázquez Albertino R, Ginel Cañamaque A, Barrot Cortés E. Evaluation of efficacy and clinical impact of FDG-PET on patients with potentially resectable non-small cell lung cancer [in Spanish]. Rev Esp Med Nucl. 2007; 26 (6): 335-344.
64. Nosotti M, Castellani M, Longari V, et al. Staging non-small lung cancer with positron emission tomography: diagnostic value, impact on patient management, and cost-effectiveness. Int Surg. 2008; 93 (5): 278-283.
65. Li M, Liu N, Hu M, et al. Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer. Lung Cancer. 2009; 63 (3): 383-386.
66. Oven Ustaalioglu BB, Gumus M, Bilici A, et al. Is there a cut-off value for standardized uptake values in positron emission tomography for predicting response to treatment and survival in patients with advanced non-small cell lung cancer? Single center experience. J BUON. 2010; 15 (3): 529-536.
67. Basu S, Kung J, Houseni M, Zhuang H, Tidmarsh GF, Alavi A. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. Q J Nucl Med Mol Imaging. 2009; 53 (1): 9-19.
68. Uesaka D, Demura Y, Ishizaki T, et al. Evaluation of dualtime-point 18 F-FDG PET for staging in patients with lung cancer. J Nucl Med. 2008; 49 (10): 1606-1612.
69. Mac Manus MP. Use of PET/CT for staging and radiation therapy planning in patients with non-small cell lung cancer. Q J Nucl Med Mol Imaging. 2010; 54 (5): 510-520.
70. de Geus-Oei LF, van der Heijden HF, Visser EP, et al. Chemotherapy response evaluation with 18 F-FDG PET in patients with non-small cell lung cancer. J Nucl Med. 2007; 48 (10): 1592-1598.
71. Nahmias C, Hanna WT, Wahl LM, Long MJ, Hubner KF, Townsend DW. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18 F-FDG PET/CT. J Nucl Med. 2007; 48 (5): 744-751.
72. Nogová L, Boellaard R, Kobe C, et al. Downregulation of 18 F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. J Nucl Med. 2009; 50 (11): 1815-1819.
73. Lauer MS, Murthy SC, Blackstone EH, Okereke IC, Rice TW. [18 F]Fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer: impact of verification bias. Arch Intern Med. 2007; 167 (2): 161-165.
74. Lardinois D, Weder W, Roudas M, et al. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol. 2005; 23 (28): 6846-6853.
75. Nakamura H, Taguchi M, Kitamura H, Nishikawa J. Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer. Gen Thorac Cardiovasc Surg. 2008; 56 (8): 404-409.
76. Carnochan FM, Walker WS. Positron emission tomography may underestimate the extent of thoracic disease in lung cancer patients. Eur J Cardiothorac Surg. 2009; 35 (5): 781-784.
77. De Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J. 2007; 29 (5): 995-1002.
78. Herder GJ, Verboom P, Smit EF, et al. Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals. Thorax. 2002; 57 (1): 11-14.
79. Hillers TK, Sauve MD, Guyatt GH. Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer. Thorax. 1994; 49 (1): 14-19.
80. Goerg C, Schwerk WB, Wolf M, Havemann K. Adrenal masses in lung cancer: sonographic diagnosis and follow-up. Eur J Cancer. 1992; 28A (8-9): 1400-1403.
81. Oliver TW Jr, Bernardino ME, Miller JI, Mansour K, Greene D, Davis WA. Isolated adrenal masses in nonsmallcell bronchogenic carcinoma. Radiology. 1984; 153(1): 217-218.
82. Burt M, Heelan RT, Coit D, et al. Prospective evaluation of unilateral adrenal masses in patients with operable nonsmall-cell lung cancer. Impact of magnetic resonance imaging. J Thorac Cardiovasc Surg. 1994; 107 (2): 584-588.
83. Heavey LR, Glazer GM, Gross BH, Francis IR, Orringer MB. The role of CT in staging radiographic T1N0M0 lung cancer. AJR Am J Roentgenol. 1986; 146 (2): 285-290.
84. Pearlberg JL, Sandler MA, Beute GH, Madrazo BL. T1N0M0 bronchogenic carcinoma: assessment by CT. Radiology. 1985; 157 (1): 187-190.
85. Eggesbø HB, Hansen G. Clinical impact of adrenal expansive lesions in bronchial carcinoma. Acta Radiol. 1996; 37 (3 Pt 1): 343-347.
86. Ettinghausen SE, Burt ME. Prospective evaluation of unilateral adrenal masses in patients with operable non-smallcell lung cancer. J Clin Oncol. 1991; 9 (8): 1462-1466.
87. Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995; 194 (1): 131-134.
88. Marom EM, McAdams HP, Erasmus JJ, et al. Staging nonsmall cell lung cancer with whole-body PET. Radiology. 1999; 212 (3): 803-809.
89. Erasmus JJ, Patz EF Jr, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18 F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997; 168 (5): 1357-1360.
90. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positronemission tomography. N Engl J Med. 2000; 343 (4): 254-261.
91. Stroobants SG, D'Hoore I, Dooms C, et al. Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-smallcell lung cancer. Clin Lung Cancer. 2003; 4 (4): 242-247.
92. Gillams A, Roberts CM, Shaw P, Spiro SG, Goldstraw P. The value of CT scanning and percutaneous fine needle aspiration of adrenal masses in biopsy-proven lung cancer. Clin Radiol. 1992; 46 (1): 18-22.
93. Macari M, Rofsky NM, Naidich DP, Megibow AJ. Nonsmall cell lung carcinoma: usefulness of unenhanced helical CT of the adrenal glands in an unmonitored environment. Radiology. 1998; 209 (3): 807-812.
94. Porte HL, Ernst OJ, Delebecq T, Métois D, Lemaitre LG, Wurtz AJ. Is computed tomography guided biopsy still necessary for the diagnosis of adrenal masses in patients with resectable non-small-cell lung cancer? Eur J Cardiothorac Surg. 1999; 15 (5): 597-601.
95. Heinz-Peer G, Hönigschnabl S, Schneider B, Niederle B, Kaserer K, Lechner G. Characterization of adrenal masses using MR imaging with histopathologic correlation. AJR Am J Roentgenol. 1999; 173 (1): 15-22.
96. Gross MD, Shapiro B, Bouffard JA, et al. Distinguishing benign from malignant euadrenal masses. Ann Intern Med. 1988; 109 (8): 613-618.
97. Chapman GS, Kumar D, Redmond J III, Munderloh SH, Gandara DR. Upper abdominal computerized tomography scanning in staging non-small cell lung carcinoma. Cancer. 1984; 54 (8): 1541-1543.
98. Nielsen ME Jr, Heaston DK, Dunnick NR, Korobkin M. Preoperative CT evaluation of adrenal glands in non-small cell bronchogenic carcinoma. AJR Am J Roentgenol. 1982; 139 (2): 317-320.
99. The American Thoracic Society and The European Respi ratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med. 1997; 156 (1): 320-332.
100. Hustinx R, Paulus P, Jacquet N, Jerusalem G, Bury T, Rigo P. Clinical evaluation of whole-body 18 F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol. 1998; 9 (4): 397-401.
101. Butler AR, Leo JS, Lin JP, et al. The value of routine cranial computed tomography in neurologically intact patients with primary carcinoma of the lung. Radiology. 1979; 131 (2): 339-401.
102. Cole FH Jr, Thomas JE, Wilcox AB, Halford HH III. Cerebral imaging in the asymptomatic preoperative bronchogenic carcinoma patient: is it worthwhile? Ann Thorac Surg. 1994; 57 (4): 838-840.
103. Colice GL, Birkmeyer JD, Black WC, Littenberg B, Silvestri G. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest. 1995; 108 (5): 1264-1271.
104. Ferrigno D, Buccheri G. Cranial computed tomography as a part of the initial staging procedures for patients with nonsmall-cell lung cancer. Chest. 1994; 106 (4): 1025-1029.
105. Jacobs L, Kinkel WR, Vincent RG. 'Silent' brain metastasis from lung carcinoma determined by computerized tomography. Arch Neurol. 1977; 34 (11): 690-693.
106. Kormas P, Bradshaw JR, Jeyasingham K. Preoperative computed tomography of the brain in non-small cell bronchogenic carcinoma. Thorax. 1992; 47 (2): 106-108.
107. Mintz BJ, Tuhrim S, Alexander S, Yang WC, Shanzer S. Intracranial metastases in the initial staging of bronchogenic carcinoma. Chest. 1984; 86 (6): 850-853.
108. Tarver RD, Richmond BD, Klatte EC. Cerebral metastases from lung carcinoma: neurological and CT correlation. Work in progress. Radiology. 1984; 153 (3): 689-692.
109. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322 (8): 494-500.
110. Davis PC, Hudgins PA, Peterman SB, et al. Diagnosis of cerebral metastases: double-dose delayed CT vs contrastenchanced MR imaging. AJR. 1991; 156 (5): 1039-1046.
111. Yokoi K, Kamiya N, Matsuguma H, et al. Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest. 1999; 115 (3): 714-719.
112. Earnest F IV, Ryu JH, Miller GM, et al. Suspected nonsmall cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection-pilot study. Radiology. 1999; 211 (1): 137-145.
113. Hochstenbag MM, Twijnstra A, Hofman P, Wouters EF, ten Velde GP. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer. 2003; 42 (2): 189-193.
114. Osada H, Nakajima Y, Taira Y, Yokote K, Noguchi T. The role of mediastinal and multi-organ CT scans in staging presumable surgical candidates with non-small-cell lung cancer. Jpn J Surg. 1987; 17 (5): 362-368.
115. Turner P, Haggith JW. Preoperative radionuclide scanning in bronchogenic carcinoma. Br J Dis Chest. 1981; 75 (3): 291-294.
116. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med. 1998; 25 (9): 1244-1247.
117. Hsia TC, Shen YY, Yen RF, Kao CH, Changlai SP. Comparing whole body 18 F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Neoplasma. 2002; 49 (4): 267-271.
118. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18 F PET. J Nucl Med. 1999; 40 (10): 1623-1629.
119. Carretta A, Ciriaco P, Canneto B, Nicoletti R, Del Maschio A, Zannini P. Therapeutic strategy in patients with non-small cell lung cancer associated to satellite pulmonary nodules. Eur J Cardiothorac Surg. 2002; 21 (6): 1100-1104.
120. Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol. 2000; 175 (1): 245-249.
121. Gupta NC, Rogers JS, Graeber GM, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest. 2002; 122 (6): 1918-1924.
122. Duysinx B, Nguyen D, Louis R, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest. 2004; 125 (2): 489-493.
123. Cerfolio RJ, Bryant AS, Ojha B, Eloubeidi M. Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. Ann Thorac Surg. 2005; 80 (4): 1207-1213.
124. Bollen EC, Goei R, van 'Thof-Grootenboer BE, Versteege CW, Engelshove HA, Lamers RJ. Interobserver variability and accuracy of computed tomographic assessment of nodal status in lung cancer. Ann Thorac Surg. 1994; 58(1): 158-162.
125. Ratto GB, Frola C, Cantoni S, Motta G. Improving clinical efficacy of computed tomographic scan in the preoperative assessment of patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 1990; 99 (3): 416-425.
126. Lee JW, Kim BS, Lee DS, et al. 1 8 F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity. Eur J Nucl Med Mol Imaging. 2009; 36 (11): 1794-1802.
127. Yen RF, Chen KC, Lee JM, et al. 1 8 F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort? Eur J Nucl Med Mol Imaging. 2008; 35 (7): 1305-1315.
128. Yang W, Fu Z, Yu J, et al. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer. 2008; 61 (1): 35-43.
129. published correction appears in Lung Cancer. 2009;63(2):305
130. Yi CA, Lee KS, Kim BT, et al. Efficacy of helical dynamic CT versus integrated PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer. AJR Am J Roentgenol. 2007; 188 (2): 318-325.
131. Turkmen C, Sonmezoglu K, Toker A, et al. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high. Clin Nucl Med. 2007; 32 (8): 607-612.
132. Ebihara A, Nomori H, Watanabe K, et al. Characteristics of advantages of positron emission tomography over computed tomography for N-staging in lung cancer patients. Jpn J Clin Oncol. 2006; 36 (11): 694-698.
133. Takamochi K, Yoshida J, Murakami K, et al. Pitfalls in lymph node staging with positron emission tomography in nonsmall cell lung cancer patients. Lung Cancer. 2005; 47 (2): 235-242.
134. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scan ning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer. 2004; 45 (1): 19-27.
135. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ Jr. Accuracy and cost-effectiveness of [18 F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest. 2004; 125 (4): 1413-1423.
136. Kimura H, Iwai N, Ando S, et al. A prospective study of indications for mediastinoscopy in lung cancer with CT findings, tumor size, and tumor markers. Ann Thorac Surg. 2003; 75 (6): 1734-1739.
137. Schillaci O, Spanu A, Scopinaro F, et al. Mediastinal lymph node involvement in non-small cell lung cancer: evaluation with 99m Tc-tetrofosmin SPECT and comparison with CT. J Nucl Med. 2003; 44 (8): 1219-1224.
138. Eggeling S, Martin T, Böttger J, Beinert T, Gellert K. Invasive staging of non-small cell lung cancer-a prospective study. Eur J Cardiothorac Surg. 2002; 22 (5): 679-684.
139. Kiernan PD, Sheridan MJ, Lamberti J, et al. Mediastinal staging of non-small cell lung carcinoma using computed and positron-emission tomography. South Med J. 2002; 95 (10): 1168-1172.
140. Nosotti M, Santambrogio L, Gasparini M, Baisi A, Bellaviti N, Rosso L. Role of (99m)tc-hexakis-2-methoxy-isobutylisonitrile in the diagnosis and staging of lung cancer. Chest. 2002; 122 (4): 1361-1364.
141. von Haag DW, Follette DM, Roberts PF, Shelton D, Segel LD, Taylor TM. Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer. J Surg Res. 2002; 103(2): 160-164.
142. Laudanski J, Kozlowski M, Nikliński J, Chyczewski L. The preoperative study of mediastinal lymph nodes metastasis in lung cancer by endoscopic ultrasonography (EUS) and helical computed tomography (CT). Lung Cancer. 2001; 34 (suppl 2): S123-S126.
143. Poncelet AJ, Lonneux M, Coche E, Weynand B, Noirhomme P; Groupe d'Oncologie Thoracique des Cliniques Saint-Luc. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg. 2001; 20(3):468-474.
144. Wallace MB, Silvestri GA, Sahai AV, et al. Endoscopic ultrasound-guided fine needle aspiration for staging patients with carcinoma of the lung. Ann Thorac Surg. 2001; 72 (6): 1861-1867.
145. Dunagan DP, Chin R Jr, McCain TW, et al. Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer. Chest. 2001; 119 (2): 333-339.
146. Kamiyoshihara M, Kawashima O, Ishikawa S, Morishita Y. Mediastinal lymph node evaluation by computed tomographic scan in lung cancer. J Cardiovasc Surg (Torino). 2001; 42 (1): 119-124.
147. Osada H, Kojima K, Tsukada H, Nakajima Y, Imamura K, Matsumoto J. Cost-effectiveness associated with the diagnosis and staging of non-small-cell lung cancer. Jpn J Thorac Cardiovasc Surg. 2001; 49 (1): 1-10.
148. Takamochi K, Nagai K, Yoshida J, et al. The role of computed tomographic scanning in diagnosing mediastinal node involvement in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2000; 119 (6): 1135-1140.
149. Saunders CAB, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg. 1999; 67 (3): 790-797.
150. Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Nishiwaki Y. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. J Thorac Cardiovasc Surg. 1999; 117 (3): 593-598.
151. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998; 16 (6): 2142-2149.
152. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. FDGPET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group. Eur J Nucl Med. 1998; 25 (11): 1495-1501.
153. Bury T, Dowlati A, Paulus P, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J. 1997; 10 (11): 2529-2534.
154. Gdeedo A, Van Schil P, Corthouts B, Van Mieghem F, Van Meerbeeck J, Van Marck E. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J. 1997; 10 (7): 1547-1551.
155. Buccheri G, Biggi A, Ferrigno D, et al. Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer. Thorax. 1996; 51 (4): 359-363.
156. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of positron emission tomography imaging in nonsmall cell lung cancer. Eur Respir J. 1996; 9 (12): 2560-2564.
157. Aaby C, Kristensen S, Nielsen SM. Mediastinal staging of non-small-cell lung cancer: computed tomography and cervical mediastinoscopy. ORL J Otorhinolaryngol Relat Spec. 1995; 57 (5): 279-285.
158. Primack SL, Lee KS, Logan PM, Miller RR, Müller NL. Bronchogenic carcinoma: utility of CT in the evaluation of patients with suspected lesions. Radiology. 1994; 193 (3): 795-800.
159. Yokoi K, Okuyama A, Mori K, et al. Mediastinal lymph node metastasis from lung cancer: evaluation with Tl-201 SPECT-comparison with CT. Radiology. 1994; 192 (3): 813-817.
160. McLoud TC, Bourgouin PM, Greenberg RW, et al. Broncho genic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 1992; 182 (2): 319-323.
161. Jolly PC, Hutchinson CH, Detterbeck F, Guyton SW, Hofer B, Anderson RP. Routine computed tomographic scans, selective mediastinoscopy, and other factors in evaluation of lung cancer. J Thorac Cardiovasc Surg. 1991; 102 (2): 266-270.
162. Cole PH, Roszkowski A, Firouz-Abadi A, Dare A. Computerised tomography does not predict N2 disease in patients with lung cancer. Aust N Z J Med. 1993; 23 (6): 688-691.
163. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology. 1991; 178 (3): 705-713.
164. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology. 1999; 213 (2): 530-536.
165. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with nonsmall-cell lung cancer: a meta-analysis. Ann Intern Med. 2003; 139 (11): 879-892.
166. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer. 1987; 60 (11): 2682-2689.
167. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fisher S. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer. 1991; 67 (6): 1544-1550.
168. Weber G, Cantero A. Glucose-6-phosphatase activity in normal, pre-cancerous, and neoplastic tissues. Cancer Res. 1955; 15 (2): 105-108.
169. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (, 1 cm), intermediate (1 to 3 cm), and large (. 3 cm) lymph node lesions. Chest. 2000; 117 (3): 773-778.
170. Detterbeck FC, Falen S, Rivera MP, Halle JS, Socinski MA. Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest. 2004; 125 (6): 2300-2308.
171. Detterbeck FC, Falen S, Rivera MP, Halle JS, Socinski MA. Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest. 2004; 125 (6): 2294-2299.
172. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med. 1996; 37 (6): 943-948.
173. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39(6):1016-1020.
174. Kim BT, Kim Y, Lee KS, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol. 1998; 170 (4): 935-939.
175. Yamamoto Y, Nishiyama Y, Kimura N, et al. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2008; 35 (2): 236-245.
176. Melek H, Gunluoglu MZ, Demir A, Akin H, Olcmen A, Dincer SI. Role of positron emission tomography in mediastinal lymphatic staging of non-small cell lung cancer. Eur J Cardiothorac Surg. 2008; 33 (2): 294-299.
177. Bernasconi M, Chhajed PN, Gambazzi F, et al. Combined transbronchial needle aspiration and positron emission tomography for mediastinal staging of NSCLC. Eur Respir J. 2006; 27 (5): 889-894.
178. Halpern BS, Schiepers C, Weber WA, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest. 2005; 128 (4): 2289-2297.
179. Demura Y, Tsuchida T, Ishizaki T, et al. 1 8 F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003; 44 (4): 540-548.
180. Fritscher-Ravens A, Bohuslavizki KH, Brandt L, et al. Mediastinal lymph node involvement in potentially resectable lung cancer: comparison of CT, positron emission tomography, and endoscopic ultrasonography with and without fine-needle aspiration. Chest. 2003; 123 (2): 442-451.
181. Gonzalez-Stawinski GV, Lemaire A, Merchant F, et al. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003; 126 (6): 1900-1905.
182. Konishi J, Yamazaki K, Tsukamoto E, et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration. 2003; 70 (5): 500-506.
183. Zimny M, Hochstenbag M, Lamers R, et al. Mediastinal staging of lung cancer with 2-[fluorine-18]-fluoro-2-deoxy-Dglucose positron emission tomography and a dual-head coincidence gamma camera. Eur Radiol. 2003; 13(4): 740-747.
184. Kernstine KH, McLaughlin KA, Menda Y, et al. Can FDGPET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? Ann Thorac Surg. 2002; 73(2):394-401.
185. Vesselle H, Pugsley JM, Vallières E, Wood DE. The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002; 124 (3): 511-519.
186. Changlai SP, Tsai SC, Chou MC, Ho YJ, Kao CH. Whole body 18 F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep. 2001; 8 (2): 337-339.
187. Tatsumi M, Yutani K, Nishimura T. Evaluation of lung cancer by 99m Tc-tetrofosmin SPECT: comparison with [18 F]FDG-PET. J Comput Assist Tomogr. 2000; 24(4): 574-580.
188. Liewald F, Grosse S, Storck M, et al. How useful is positron emission tomography for lymphnode staging in non-smallcell lung cancer? Thorac Cardiovasc Surg. 2000; 48(2): 93-96.
189. Roberts PF, Follette DM, von Haag D, et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg. 2000; 70 (4): 1154-1159.
190. Magnani P, Carretta A, Rizzo G, et al. FDG/PET and spiral CT image fusion for medistinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg (Torino). 1999; 40 (5): 741-748.
191. Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske SN. Lymph node staging in non-small cell lung cancer: evaluation by [18 F]FDG positron emission tomography (PET). Thorax. 1997; 52 (5): 438-441.
192. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 1997; 202 (2): 441-446.
193. Sazon DA, Santiago SM, Soo Hoo GW, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med. 1996; 153 (1): 417-421.
194. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg. 1996; 111 (3): 642-648.
195. Chin R Jr, Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med. 1995; 152 (6 Pt 1): 2090-2096.
196. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 1994; 191 (2): 371-377.
197. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003; 229 (2): 526-533.
198. Lardinois D, Weder W, Hany TF, et al. Staging of nonsmall-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003; 348 (25): 2500-2507.
199. Roman MR, Rossleigh MA, Angelides S, Walker BM, Dixon J. Staging and managing lung tumors using F-18 FDG coincidence detection. Clin Nucl Med. 2001; 26 (5): 383-388.
200. Billé A, Pelosi E, Skanjeti A, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg. 2009; 36 (3): 440-445.
201. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg. 2004; 78 (3): 1017-1023.
202. Fischer BM, Lassen U, Højgaard L. PET-CT in preoperative staging of lung cancer. N Engl J Med. 2011; 364 (10): 980-981.
203. Lee HJ, Kim YT, Kang WJ, Lee HJ, Kang CH, Kim JH. Integrated positron-emission tomography for nodal staging in lung cancer. Asian Cardiovasc Thorac Ann. 2009; 17 (6): 622-626.
204. Perigaud C, Bridji B, Roussel JC, et al. Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer. Eur J Cardiothorac Surg. 2009; 36 (4): 731-736.
205. Plathow C, Aschoff P, Lichy MP, et al. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer-initial results. Invest Radiol. 2008; 43 (5): 290-297.
206. Sanli M, Isik AF, Zincirkeser S, et al. Reliability of positron emission tomography-computed tomography in identification of mediastinal lymph node status in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009; 138 (5): 1200-1205.
207. Shin KM, Lee KS, Shim YM, et al. FDG PET/CT and mediastinal nodal metastasis detection in stage T1 non-small cell lung cancer: prognostic implications. Korean J Radiol. 2008; 9 (6): 481-489.
208. Toba H, Kondo K, Otsuka H, et al. Diagnosis of the presence of lymph node metastasis and decision of operative indication using fluorodeoxyglucose- positron emission tomography and computed tomography in patients with primary lung cancer. J Med Invest. 2010; 57 (3-4): 305-313.
209. Usuda K, Zhao XT, Sagawa M, et al. Diffusion-weighted imaging is superior to positron emission tomography in the detection and nodal assessment of lung cancers. Ann Thorac Surg. 2011; 91 (6): 1689-1695.
210. Yi CA, Shin KM, Lee KS, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008; 248 (2): 632-642.
211. Herth FJ, Eberhardt R, Krasnik M, Ernst A. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest. 2008; 133 (4): 887-891.
212. Herth FJ, Ernst A, Eberhardt R, Vilmann P, Dienemann H, Krasnik M. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically normal mediastinum. Eur Respir J. 2006; 28 (5): 910-914.
213. Crisci R, Di Cesare E, Lupattelli L, Coloni GF. MR study of N2 disease in lung cancer: contrast-enhanced method using gadolinium-DTPA. Eur J Cardiothorac Surg. 1997; 11 (2): 214-217.
214. Kernstine KH, Stanford W, Mullan BF, et al. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg. 1999; 68(3): 1022-1028.
215. Heelan RT, Demas BE, Caravelli JF, et al. Superior sulcus tumors: CT and MR imaging. Radiology. 1989; 170 (3 Pt 1): 637-641.
216. Manfredi R, Pirronti T, Bonomo L, Marano P. Accuracy of computed tomography and magnetic resonance imaging in staging bronchogenic carcinoma. MAGMA. 1996; 4 (3-4): 257-262.
217. Padovani B, Mouroux J, Seksik L, et al. Chest wall invasion by bronchogenic carcinoma: evaluation with MR imaging. Radiology. 1993; 187 (1): 33-38.
218. Shiotani S, Sugimura K, Sugihara M, et al. Diagnosis of chest wall invasion by lung cancer: useful criteria for exclusion of the possibility of chest wall invasion with MR imaging. Radiat Med. 2000; 18 (5): 283-290.
219. Cybulsky IJ, Bennett WF. Mediastinoscopy as a routine outpatient procedure. Ann Thorac Surg. 1994; 58 (1): 176-178.
220. Selby JH Jr, Leach CL, Heath BJ, Neely WA. Local anesthesia for mediastinoscopy: experience with 450 consecutive cases. Am Surg. 1978; 44 (10): 679-682.
221. Vallières E, Pagé A, Verdant A. Ambulatory mediastinoscopy and anterior mediastinotomy. Ann Thorac Surg. 1991; 52 (5): 1122-1126.
222. Kiser AC, Detterbeck FC. General aspects of surgical treatment. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and Treatment of Lung Cancer: an Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA: WB Saunders; 2001 :133-147.
223. Leschber G, Sperling D, Klemm W, Merk J. Does videomediastinoscopy improve the results of conventional mediastinoscopy? Eur J Cardiothorac Surg. 2008; 33 (2): 289-293.
224. Venissac N, Alifano M, Mouroux J. Video-assisted mediastinoscopy: experience from 240 consecutive cases. Ann Thorac Surg. 2003; 76 (1): 208-212.
225. Kim HK, Choi YS, Kim K, et al. Outcomes of mediastinoscopy and surgery with or without neoadjuvant therapy in patients with non-small cell lung cancer who are N2 negative on positron emission tomography and computed tomography. J Thorac Oncol. 2011; 6 (2): 336-342.
226. Park HK, Jeon K, Koh WJ, et al. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT. Respirology. 2010; 15 (8): 1179-1184.
227. Block MI. Transition from mediastinoscopy to endoscopic ultrasound for lung cancer staging. Ann Thorac Surg. 2010; 89 (3): 885-890.
228. Anraku M, Miyata R, Compeau C, Shargall Y. Videoassisted mediastinoscopy compared with conventional mediastinoscopy: mediastinoscopy: are we doing better? Ann Thorac Surg. 2010; 89 (5): 1577-1581.
229. Annema JT, van Meerbeeck JP, Rintoul RC, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA. 2010; 304 (20): 2245-2252.
230. Meyers BF, Haddad F, Siegel BA, et al. Cost-effectiveness of routine mediastinoscopy in computed tomographyand positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg. 2006; 131 (4): 822-829.
231. Lemaire A, Nikolic I, Petersen T, et al. Nine-year single center experience with cervical mediastinoscopy: complications and false negative rate. Ann Thorac Surg. 2006; 82(4): 1185-1189.
232. Fibla JJ, Molins L, Simon C, Perez J, Vidal G. The yield of mediastinoscopy with respect to lymph node size, cell type, and the location of the primary tumor. J Thorac Oncol. 2006; 1 (5): 430-433.
233. Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest. 2006; 130 (6): 1791-1795.
234. Choi YS, Shim YM, Kim J, Kim K. Mediastinoscopy in patients with clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2003; 75 (2): 364-366.
235. Gürses A, Turna A, Bedirhan MA, et al. The value of mediastinoscopy in preoperative evaluation of mediastinal involvement in non-small-cell lung cancer patients with clinical NO disease. Thorac Cardiovasc Surg. 2002; 50 (3): 174-177.
236. Hammoud ZT, Anderson RC, Meyers BF, et al. The current role of mediastinoscopy in the evaluation of thoracic disease. J Thorac Cardiovasc Surg. 1999; 118 (5): 894-899.
237. Ebner H, Marra A, Butturini E, De Santis F. Clinical value of cervical mediastinoscopy in the staging of bronchial carcinoma. Ann Ital Chir. 1999; 70 (6): 873-879.
238. Gdeedo A, Van Schil P, Corthouts B, Van Mieghem F, Van Meerbeeck J, Van Marck E. Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma. Eur J Cardiothorac Surg. 1997; 12 (2): 224-227.
239. De Leyn P, Schoonooghe P, Deneffe G, et al. Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease). Eur J Cardiothorac Surg. 1996; 10:649-654.
240. Dillemans B, Deneffe G, Verschakelen J, Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. Eur J Cardiothorac Surg. 1994; 8 (1): 37-42.
241. Ríordáin DS, Buckley DJ, Aherne T. Mediastinoscopy as a predictor of resectability in patients with bronchogenic carcinoma. Ir J Med Sci. 1991; 160 (9): 291-292.
242. Pagé A, Nakhlé G, Mercier C, et al. Surgical treatment of bronchogenic carcinoma: the importance of staging in evaluating late survival. Can J Surg. 1987; 30 (2): 96-99.
243. Luke WP, Pearson FG, Todd TR, Patterson GA, Cooper JD. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. J Thorac Cardiovasc Surg. 1986; 91 (1): 53-56.
244. Coughlin M, Deslauriers J, Beaulieu M, et al. Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann Thorac Surg. 1985; 40 (6): 556-560.
245. Brion JP, Depauw L, Kuhn G, et al. Role of computed tomography and mediastinoscopy in preoperative staging of lung carcinoma. J Comput Assist Tomogr. 1985; 9 (3): 480-484.
246. Deneffe G, Lacquet LM, Gyselen A. Cervical mediastinoscopy and anterior mediastinotomy in patients with lung cancer and radiologically normal mediastinum. Eur J Respir Dis. 1983; 64 (8): 613-619.
247. Lardinois D, Schallberger A, Betticher D, Ris HB. Postinduction video-mediastinoscopy is as accurate and safe as video-mediastinoscopy in patients without pretreatment for potentially operable non-small cell lung cancer. Ann Thorac Surg. 2003; 75 (4): 1102-1106.
248. Staples CA, Müller NL, Miller RR, Evans KG, Nelems B. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology. 1988; 167 (2): 367-372.
249. Van Den Bosch JM, Gelissen HJ, Wagenaar SS. Exploratory thoracotomy in bronchial carcinoma. J Thorac Cardiovasc Surg. 1983; 85 (5): 733-737.
250. Sayar A, Citak N, Metin M, et al. Comparison of videoassisted mediastinoscopy and video-assisted mediastinoscopic lymphadenectomy for lung cancer. Gen Thorac Cardiovasc Surg. 2011; 59 (12): 793-798.
251. Kimura H, Yasufuku K, Ando S, et al. Indications for mediastinoscopy and comparison of lymph node dissections in candidates for lung cancer surgery. Lung Cancer. 2007; 56 (3): 349-355.
252. Patterson GA, Piazza D, Pearson FG, et al. Significance of metastatic disease in subaortic lymph nodes. Ann Thorac Surg. 1987; 43 (2): 155-159.
253. Detterbeck FC, Jones DR. Surgical treatment of stage IIIa (N2) non-small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and Teatment of Lung Cancer: an Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA: WB Saunders; 2001 :244-256
254. Barendregt WB, Deleu HW, Joosten HJ, Berg W, Janssen JP. The value of parasternal mediastinoscopy in staging bronchial carcinoma. Eur J Cardiothorac Surg. 1995; 9 (11): 655-658.
255. Nechala P, Graham AJ, McFadden SD, Grondin SC, Gelfand G. Retrospective analysis of the clinical performance of anterior mediastinotomy. Ann Thorac Surg. 2006; 82 (6): 2004-2009.
256. Freixinet Gilart J, García PG, de Castro FR, Suárez PR, Rodríguez NS, de Ugarte AV. Extended cervical mediastinoscopy in the staging of bronchogenic carcinoma. Ann Thorac Surg. 2000; 70 (5): 1641-1643.
257. Ginsberg RJ, Rice TW, Goldberg M, Waters PF, Schmocker BJ. Extended cervical mediastinoscopy. A single staging procedure for bronchogenic carcinoma of the left upper lobe. J Thorac Cardiovasc Surg. 1987; 94 (5): 673-678.
258. Metin M, Citak N, Sayar A, et al. The role of extended cervical mediastinoscopy in staging of non-small cell lung cancer of the left lung and a comparison with integrated positron emission tomography and computed tomography: does integrated positron emission tomography and computed tomography reduce the need for invasive procedures? J Thorac Oncol. 2011; 6 (10): 1713-1719.
259. Obiols C, Call S, Rami-Porta R, et al. Extended cervical mediastinoscopy: mature results of a clinical protocol for staging bronchogenic carcinoma of the left lung. Eur J Cardiothorac Surg. 2012; 41 (5): 1043-1046.
260. Cerfolio RJ, Bryant AS, Eloubeidi MA. Accessing the aortopulmonary window (#5) and the paraaortic (#6) lymph nodes in patients with non-small cell lung cancer. Ann Thorac Surg. 2007; 84 (3): 940-945.
261. Massone PP, Lequaglie C, Magnani B, Ferro F, Cataldo I. The real impact and usefulness of video-assisted thoracoscopic surgery in the diagnosis and therapy of clinical lymphadenopathies of the mediastinum. Ann Surg Oncol. 2003; 10 (10): 1197-1202.
262. Sebastián-Quetglás F, Molins L, Baldó X, Buitrago J, Vidal G; Spanish Video-assisted Thoracic Surgery Study Group. Clinical value of video-assisted thoracoscopy for preoperative staging of non-small cell lung cancer. A prospective study of 105 patients. Lung Cancer. 2003; 42 (3): 297-301.
263. De Giacomo T, Rendina EA, Venuta F, Della Rocca G, Ricci C. Thoracoscopic staging of IIIB non-small cell lung cancer before neoadjuvant therapy. Ann Thorac Surg. 1997; 64 (5): 1409-1411.
264. Landreneau RJ, Hazelrigg SR, Mack MJ, et al. Thoracoscopic mediastinal lymph node sampling: useful for mediastinal lymph node stations inaccessible by cervical mediastinoscopy. J Thorac Cardiovasc Surg. 1993; 106 (3): 554-558.
265. Loscertales J, Jimenez-Merchan R, Arenas-Linares C, Giron-Arjona JC, Congregado-Loscertales M. The use of videoassisted thoracic surgery in lung cancer: evaluation of resectability in 296 patients and 71 pulmonary exeresis with radical lymphadenectomy. Eur J Cardiothorac Surg. 1997; 12 (6): 892-897.
266. Roberts JR, Blum MG, Arildsen R, et al. Prospective comparison of radiologic, thoracoscopic, and pathologic staging in patients with early non-small cell lung cancer. Ann Thorac Surg. 1999; 68 (4): 1154-1158.
267. Wain JC. Video-assisted thoracoscopy and the staging of lung cancer. Ann Thorac Surg. 1993; 56 (3): 776-778.
268. Roviaro GC, Varoli F, Rebuffat C, et al. Videothoracoscopic operative staging for lung cancer. Int Surg. 1996; 81 (3): 252-254.
269. Protopapas Z, Westcott JL. Transthoracic needle biopsy of mediastinal lymph nodes for staging lung and other cancers. Radiology. 1996; 199 (2): 489-496.
270. Böcking A, Klose KC, Kyll HJ, Hauptmann S. Cytologic versus histologic evaluation of needle biopsy of the lung, hilum and mediastinum. Sensitivity, specificity and typing accuracy. Acta Cytol. 1995; 39 (3): 463-471.
271. de Gregorio Ariza MA, Alfonso Aguirán ER, Villavieja Atance JL, et al. Transthoracic aspiration biopsy of pulmonary and mediastinal lesions. Eur J Radiol. 1991; 12 (2): 98-103.
272. Moinuddin SM, Lee LH, Montgomery JH. Mediastinal needle biopsy. AJR Am J Roentgenol. 1984; 143 (3): 531-532.
273. Westcott JL. Percutaneous needle aspiration of hilar and mediastinal masses. Radiology. 1981; 141 (2): 323-329.
274. Bilaçeroǧlu S, Caǧiotariotaciota U, Günel O, Bayol U, Perim K. Comparison of rigid and flexible transbronchial needle aspiration in the staging of bronchogenic carcinoma. Respiration. 1998; 65 (6): 441-449.
275. Garpestad E, Goldberg S, Herth F, et al. CT fluoroscopic guidance for transbronchial needle aspiration: an experience in 35 patients. Chest. 2001; 119 (2): 329-332.
276. Rodríguez de Castro F, Rey A, Caminero J, et al. Transbronchial fine needle aspiration in clinical practice. Cytopathology. 1995; 6 (1): 22-29.
277. Vansteenkiste J, Lacquet LM, Demedts M, Deneffe G, Verbeken E. Transcarinal needle aspiration biopsy in the staging of lung cancer. Eur Respir J. 1994; 7 (2): 265-268.
278. Fernández-Villar A, Botana M, Leiro V, González A, Represas C, Ruano-Raviña A. Validity and reliability of transbronchial needle aspiration for diagnosing mediastinal adenopathies. BMC Pulm Med. 2010; 10 : 24.
279. Harrow EM, Abi-Saleh W, Blum J, et al. The utility of transbronchial needle aspiration in the staging of bronchogenic carcinoma. Am J Respir Crit Care Med. 2000; 161 (2 Pt 1): 601-607.
280. Katis K. Bronchoscopic needle aspiration in mediastinal staging of patients with bronchogenic carcinoma. J Bronchol. 1998; 5 : 195-199.
281. Mak G, Chitkara R, Segall G, et al. Transbronchial needle aspiration and positron emission tomography in the diagnosis of lung cancer. J Bronchol. 2004; 11 : 237-241.
282. Medford AR, Agrawal S, Free CM, Bennett JA. A prospective study of conventional transbronchial needle aspiration: performance and cost utility. Respiration. 2010; 79 (6): 482-489.
283. Melloni G, Casiraghi M, Bandiera A, et al. Transbronchial needle aspiration in lung cancer patients suitable for operation with positive mediastinal positron emission tomography. Ann Thorac Surg. 2009; 87 (2): 373-378.
284. Patelli M, Lazzari Agli L, Poletti V, et al. Role of fiberscopic transbronchial needle aspiration in the staging of N2 disease due to non-small cell lung cancer. Ann Thorac Surg. 2002; 73 (2): 407-411.
285. Rakha EA, Naik V, Chaudry Z, Baldwin D, Soomro IN. Cytological assessment of conventional transbronchial fine needle aspiration of lymph nodes. Cytopathology. 2010; 21 (1): 27-34.
286. Ratto GB, Mereu C, Motta G. The prognostic significance of preoperative assessment of mediastinal lymph nodes in patients with lung cancer. Chest. 1988; 93 (4): 807-813.
287. Rodríguez de Castro F, Díaz López F, Serdà GJ, López AR, Gilart JF, Cabrera Navarro P. Relevance of training in transbronchial fine-needle aspiration technique. Chest. 1997; 111 (1): 103-105.
288. Rong F, Cui B. CT scan directed transbronchial needle aspiration biopsy for mediastinal nodes. Chest. 1998; 114 (1): 36-39.
289. Schenk DA, Chambers SL, Derdak S, et al. Comparison of the Wang 19-gauge and 22-gauge needles in the mediastinal staging of lung cancer. Am Rev Respir Dis. 1993; 147 (5): 1251-1258.
290. Schenk DA, Bower JH, Bryan CL, et al. Transbronchial needle aspiration staging of bronchogenic carcinoma. Am Rev Respir Dis. 1986; 134 (1): 146-148.
291. Schenk DA, Strollo PJ, Pickard JS, et al. Utility of the Wang 18-gauge transbronchial histology needle in the staging of bronchogenic carcinoma. Chest. 1989; 96 (2): 272-274.
292. Selçuk ZT, Firat P. The diagnostic yield of transbronchial needle aspiration in superior vena cava syndrome. Lung Cancer. 2003; 42 (2): 183-188.
293. Shah PL, Singh S, Bower M, Livni N, Padley S, Nicholson AG. The role of transbronchial fine needle aspiration in an integrated care pathway for the assessment of patients with suspected lung cancer. J Thorac Oncol. 2006; 1 (4): 324-327.
294. Shannon JJ, Bude RO, Orens JB, et al. Endobronchial ultrasound-guided needle aspiration of mediastinal adenopathy. Am J Respir Crit Care Med. 1996; 153 (4 Pt 1): 1424-1430.
295. Stratakos G, Porfyridis I, Papas V, et al. Exclusive diagnostic contribution of the histology specimens obtained by 19-gauge transbronchial aspiration needle in suspected malignant intrathoracic lymphadenopathy. Chest. 2008; 133 (1): 131-136.
296. Utz JP, Patel AM, Edell ES. The role of transcarinal needle aspiration in the staging of bronchogenic carcinoma. Chest. 1993; 104 (4): 1012-1016.
297. Wallace MB, Pascual JM, Raimondo M, et al. Minimally invasive endoscopic staging of suspected lung cancer. JAMA. 2008; 299 (5): 540-546.
298. Wang KP, Brower R, Haponik EF, Siegelman S. Flexible transbronchial needle aspiration for staging of bronchogenic carcinoma. Chest. 1983; 84 (5): 571-576.
299. Wilsher ML, Gurley AM. Transtracheal aspiration using rigid bronchoscopy and a rigid needle for investigating mediastinal masses. Thorax. 1996; 51 (2): 197-199.
300. Shure D, Fedullo PF. The role of transcarinal needle aspiration in the staging of bronchogenic carcinoma. Chest. 1984; 86 (5): 693-696.
301. Holty JE, Kuschner WG, Gould MK. Accuracy of transbronchial needle aspiration for mediastinal staging of nonsmall cell lung cancer: a meta-analysis. Thorax. 2005; 60 (11): 949-955.
302. Fritscher-Ravens A, Soehendra N, Schirrow L, et al. Role of transesophageal endosonography-guided fine-needle aspiration in the diagnosis of lung cancer. Chest. 2000; 117 (2): 339-345.
303. Gress FG, Savides TJ, Sandler A, et al. Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography in the preoperative staging of non-small-cell lung cancer: a comparison study. Ann Intern Med. 1997; 127 (8 Pt 1): 604-612.
304. Kramer H, Koëter GH, Sleijfer DT, van Putten JW, Groen HJ. Endoscopic ultrasound-guided fine-needle aspiration in patients with mediastinal abnormalities and previous extrathoracic malignancy. Eur J Cancer. 2004; 40(4): 559-562.
305. Silvestri GA, Hoffman BJ, Bhutani MS, et al. Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer. Ann Thorac Surg. 1996; 61(5): 1441-1445.
306. Wiersema MJ, Vazquez-Sequeiros E, Wiersema LM. Evaluation of mediastinal lymphadenopathy with endoscopic US-guided fine-needle aspiration biopsy. Radiology. 2001; 219 (1): 252-257.
307. Annema JT, Bohoslavsky R, Burgers S, et al. Implementation of endoscopic ultrasound for lung cancer staging. Gastrointest Endosc. 2010; 71(1):64-70.
308. Herth FJ, Krasnik M, Kahn N, Eberhardt R, Ernst A. Combined endoscopic-endobronchial ultrasound-guided fine-needle aspiration of mediastinal lymph nodes through a single bronchoscope in 150 patients with suspected lung cancer. Chest. 2010; 138 (4): 790-794.
309. Szlubowski A, Zieliński M, Soja J, et al. A combined approach of endobronchial and endoscopic ultrasound-guided needle aspiration in the radiologically normal mediastinum in nonsmall-cell lung cancer staging-a prospective trial. Eur J Cardiothorac Surg. 2010; 37 (5): 1175-1179.
310. Talebian M, von Bartheld MB, Braun J, et al. EUS-FNA in the preoperative staging of non-small cell lung cancer. Lung Cancer. 2010; 69 (1): 60-65.
311. Nadarajan P, Sulaiman I, Kent B, Breslin N, Moloney ED, Lane SJ. Endoscopic ultrasound with fine needle aspiration and biopsy in lung cancer and isolated mediastinal lymphadenopathy. Ir Med J. 2010; 103 (3): 75-77.
312. Kalade AV, Eddie Lau WF, Conron M, et al. Endoscopic ultrasound-guided fine-needle aspiration when combined with positron emission tomography improves specificity and overall diagnostic accuracy in unexplained mediastinal lymphadenopathy and staging of non-small-cell lung cancer. Intern Med J. 2008; 38 (11): 837-844.
313. Tournoy KG, Ryck FD, Vanwalleghem L, et al. The yield of endoscopic ultrasound in lung cancer staging: does lymph node size matter? J Thorac Oncol. 2008; 3 (3): 245-249.
314. Sawhney MS, Bakman Y, Holmstrom AM, Nelson DB, Lederle FA, Kelly RF. Impact of preoperative endoscopic ultrasound on non-small cell lung cancer staging. Chest. 2007; 132 (3): 916-921.
315. Fernández-Esparrach G, Ginès A, Belda J, et al. Transesophageal ultrasound-guided fine needle aspiration improves mediastinal staging in patients with non-small cell lung cancer and normal mediastinum on computed tomography. Lung Cancer. 2006; 54 (1): 35-40.
316. Eloubeidi MA, Cerfolio RJ, Chen VK, Desmond R, Syed S, Ojha B. Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg. 2005; 79 (1): 263-268.
317. Annema JT, Versteegh MI, Veseliç M, Voigt P, Rabe KF. Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging. J Clin Oncol. 2005; 23 (33): 8357-8361.
318. Annema JT, Versteegh MI, Veseliç M, et al. Endoscopic ultrasound
319. Eloubeidi MA, Tamhane A, Chen VK, Cerfolio RJ. Endoscopic ultrasound-guided fine-needle aspiration in patients with non-small cell lung cancer and prior negative mediastinoscopy. Ann Thorac Surg. 2005; 80 (4): 1231-1239.
320. Larsen SS, Vilmann P, Krasnik M, et al. Endoscopic ultrasound guided biopsy performed routinely in lung cancer staging spares futile thoracotomies: preliminary results from a randomised clinical trial. Lung Cancer. 2005; 49 (3): 377-385.
321. Caddy G, Conron M, Wright G, Desmond P, Hart D, Chen RY. The accuracy of EUS-FNA in assessing mediastinal lymphadenopathy and staging patients with NSCLC. Eur Respir J. 2005; 25 (3): 410-415.
322. LeBlanc JK, Devereaux BM, Imperiale TF, et al. Endoscopic ultrasound in non-small cell lung cancer and negative mediastinum on computed tomography. Am J Respir Crit Care Med. 2005; 171 (2): 177-182.
323. Wallace MB, Ravenel J, Block MI, et al. Endoscopic ultrasound in lung cancer patients with a normal mediastinum on computed tomography. Ann Thorac Surg. 2004; 77 (5): 1763-1768.
324. Annema JT, Hoekstra OS, Smit EF, Veseliç M, Versteegh MI, Rabe KF. Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA. Lung Cancer. 2004; 44 (1): 53-60.
325. Larsen SS, Krasnik M, Vilmann P, et al. Endoscopic ultrasound guided biopsy of mediastinal lesions has a major impact on patient management. Thorax. 2002; 57 (2): 98-103.
326. Wallace MB, Ravenel J, Block MI, et al. Endoscopic ultrasound in lung cancer patients with a normal mediastinum on computed tomography. Ann Thorac Surg. 2004; 77 (5): 1763-1768.
327. Varadarajulu S, Schmulewitz N, Wildi SM, et al. Accuracy of EUS in staging of T4 lung cancer. Gastrointest Endosc. 2004; 59 (3): 345-348.
328. published correction appears in Gastrointest Endosc. 2004;59(6):752
329. Aabakken L, Silvestri GA, Hawes R, Reed CE, Marsi V, Hoffman B. Cost-efficacy of endoscopic ultrasonography with fine-needle aspiration vs. mediastinotomy in patients with lung cancer and suspected mediastinal adenopathy. Endoscopy. 1999; 31 (9): 707-711.
330. Harewood GC, Wiersema MJ, Edell ES, Liebow M. Costminimization analysis of alternative diagnostic approaches in a modeled patient with non-small cell lung cancer and subcarinal lymphadenopathy. Mayo Clin Proc. 2002; 77 (2): 155-164.
331. Lee BE, Kletsman E, Rutledge JR, Korst RJ. Utility of endobronchial ultrasound-guided mediastinal lymph node biopsy in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012; 143 (3): 585-590.
332. Yasufuku K, Pierre A, Darling G, et al. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg. 2011; 142(6):1393-1400.e1.
333. Memoli JS, El-Bayoumi E, Pastis NJ, et al. Using endobronchial ultrasound features to predict lymph node metastasis in patients with lung cancer. Chest. 2011; 140 (6): 1550-1556.
334. Cetinkaya E, Seyhan EC, Ozgul A, et al. Efficacy of convex probe endobronchial ultrasound (CP-EBUS) assisted transbronchial needle aspiration for mediastinal staging in non-small cell lung cancer cases with mediastinal lymphadenopathy. Ann Thorac Cardiovasc Surg. 2011; 17 (3): 236-242.
335. Ye T, Hu H, L uo X, Chen H. The role of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) for qualitative diagnosis of mediastinal and hilar lymphadenopathy: a prospective analysis. BMC Cancer. 2011; 11 : 100.
336. Steinfort DP, Hew MJ, Irving LB. Bronchoscopic evaluation of the mediastinum using endobronchial ultrasound: a description of the first 216 cases carried out at an Australian tertiary hospital. Intern Med J. 2011; 41 (12): 815-824.
337. Hwangbo B, Lee GK, Lee HS, et al. Transbronchial and transesophageal fine-needle aspiration using an ultrasound bronchoscope in mediastinal staging of potentially operable lung cancer. Chest. 2010; 138 (4): 795-802.
338. Cerfolio RJ, Bryant AS, Eloubeidi MA, et al. The true false negative rates of esophageal and endobronchial ultrasound in the staging of mediastinal lymph nodes in patients with nonsmall cell lung cancer. Ann Thorac Surg. 2010; 90(2): 427-434.
339. Sun W, Song K, Zervos M, et al. The diagnostic value of endobronchial ultrasound-guided needle biopsy in lung cancer and mediastinal adenopathy. Diagn Cytopathol. 2010; 38 (5): 337-342.
340. Nakajima T, Yasufuku K, Nakajima M, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for lymph node staging in patients with non-small cell lung cancer in non-operable patients pursuing radiotherapy as a primary treatment. J Thorac Oncol. 2010; 5 (5): 606-611.
341. Gilbert S, Wilson DO, Christie NA, et al. Endobronchial ultrasound as a diagnostic tool in patients with mediastinal lymphadenopathy. Ann Thorac Surg. 2009; 88(3):896-900.
342. Ømark Petersen H, Eckardt J, Hakami A, Olsen KE, Jørgensen OD. The value of mediastinal staging with endobronchial ultrasound-guided transbronchial needle aspiration in patients with lung cancer. Eur J Cardiothorac Surg. 2009; 36 (3): 465-468.
343. Fielding D, Windsor M. Endobronchial ultrasound convexprobe transbronchial needle aspiration as the first diagnostic test in patients with pulmonary masses and associated hilar or mediastinal nodes. Intern Med J. 2009; 39 (7): 435-440.
344. Hwangbo B, Kim SK, Lee HS, et al. Application of endobronchial ultrasound-guided transbronchial needle aspiration following integrated PET/CT in mediastinal staging of potentially operable non-small cell lung cancer. Chest. 2009; 135 (5): 1280-1287.
345. Szlubowski A, Kuzdzał J, Kołodziej M, et al. Endobronchial ultrasound-guided needle aspiration in the non-small cell lung cancer staging. Eur J Cardiothorac Surg. 2009; 35(2): 332-335.
346. Rintoul RC, Tournoy KG, El Daly H, et al. EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol. 2009; 4 (1): 44-48.
347. Bauwens O, Dusart M, Pierard P, et al. Endobronchial ultrasound and value of PET for prediction of pathological results of mediastinal hot spots in lung cancer patients. Lung Cancer. 2008; 61 (3): 356-361.
348. Lee HS, Lee GK, Lee HS, et al. Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer: how many aspirations per target lymph node station? Chest. 2008; 134 (2): 368-374.
349. Herth FJ, Rabe KF, Gasparini S, Annema JT. Transbronchial and transoesophageal (ultrasound-guided) needle aspirations for the analysis of mediastinal lesions. Eur Respir J. 2006; 28 (6): 1264-1275.
350. Yasufuku K, Nakajima T, Motoori K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest. 2006; 130 (3): 710-718.
351. Yasufuku K, Chiyo M, Koh E, et al. Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer. Lung Cancer. 2005; 50 (3): 347-354.
352. Yasufuku K, Chiyo M, Sekine Y, et al. Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest. 2004; 126 (1): 122-128.
353. Herth FJ, Eberhardt R, Vilmann P, Krasnik M, Ernst A. Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes. Thorax. 2006; 61 (9): 795-798.
354. Ohnishi R, Yasuda I, Kato T, et al. Combined endobronchial and endoscopic ultrasound-guided fine needle aspiration for mediastinal nodal staging of lung cancer. Endoscopy. 2011; 43 (12): 1082-1089.
355. Vilmann P, Krasnik M, Larsen SS, Jacobsen GK, Clementsen P. Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy: a combined approach in the evaluation of mediastinal lesions. Endoscopy. 2005; 37 (9): 833-839.
356. Detterbeck F, Puchalski J, Rubinowitz A, Cheng D. Classification of the thoroughness of mediastinal staging of lung cancer. Chest. 2010; 137 (2): 436-442.
357. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med. 2000; 27 (11): 1598-1609.
358. Port JL, Andrade RS, Levin MA, et al. Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less. J Thorac Cardiovasc Surg. 2005; 130 (6): 1611-1615.
359. Ramnath N, Dilling TJ, Harris LJ. et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5)(suppl): e314S-e340S.
360. De Waele M, Hendriks J, Lauwers P, et al. Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy. Eur J Cardiothorac Surg. 2006; 29 (2): 240-243.
361. Meersschaut D, Vermassen F, Brutel de la Rivière A, Knaepen PJ, Van den Bosch JM, Vanderschueren R. Repeat mediastinoscopy in the assessment of new and recurrent lung neoplasm. Ann Thorac Surg. 1992; 53 (1): 120-122.
362. Van Schil P, van der Schoot J, Poniewierski J, et al. Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. Lung Cancer. 2002; 37 (3): 281-285.